BridgeBio Pharma To Present Detailed Results From The Phase 3 ATTRibute Study In Patients With Transthyretin Amyloidosis Cardiomyopathy At European Society Of Cardiology Congress 2023
Portfolio Pulse from Happy Mohamed
BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced that detailed Phase 3 results from its study of acoramidis in transthyretin amyloid cardiomyopathy will be presented at the European Society of Cardiology Congress 2023. The company will also host an investor call to discuss the results. In addition, BridgeBio will present a poster on the observed near-complete TTR stabilization of acoramidis in patients with variant transthyretin amyloidosis.
August 24, 2023 | 8:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BridgeBio Pharma's announcement of presenting detailed Phase 3 results of acoramidis study could potentially impact the company's stock positively.
The announcement of presenting detailed Phase 3 results of a study is a significant milestone for any biopharmaceutical company. This could potentially attract more investors, leading to a positive impact on the company's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100